ESMO 2023: Does stopping VEGFR TKI treatment and continuing immunotherapy influence the survival of patients on combination therapy?
In many countries, combinations of VEGFR TKI anti-cancer mediations plus [...]
Pembrolizumab plus lenvatinib for non-clear cell kidney cancer
Immunotherapy combinations are becoming the standard treatment for people with [...]
Adjuvant therapy for kidney cancer
Adjuvant therapy aims to reduce the risk of the cancer [...]
TKI treatment breaks may not affect outcomes in kidney cancer
The results of the phase 2/3 STAR trial were published [...]
Survival after second-line therapy in patients with metastatic kidney cancer treated with first-line immunotherapy combinations
This study looked at real world information from patients with [...]
Side effect management for kidney cancer treatments
At the International Kidney Cancer Symposium (IKCS) in the USA [...]
Treatment of rare subtypes of kidney cancer
At the International Kidney Cancer Symposium (IKCS) in North America [...]
ESMO 2022: Combination of cabozantinib, nivolumab and ipilimumab for patients with advanced kidney cancer with high-risk disease
The results of COSMIC-131 were presented at the European Society [...]
Reduced starting dose of TKI is comparable to a full dose in metastatic kidney cancer
A study published in the Journal of Hematology Oncology Pharmacy [...]
ASCO 2022: Sequencing of kidney cancer medicines
During the American Society of Clinical Oncology (ASCO) Annual Meeting [...]
